INTERVIEW: ARV Supplies At Risk If Teva Bid Succeeds, Fears Mylan
This article was originally published in PharmAsia News
Executive Summary
At least one senior board member of Mylan is apprehensive about supplies of antiretroviral drugs (ARVs) to low income countries from the generic firm’s Indian sites should Teva succeed in its acquisition bid.